Improving Outcomes In Systemic Autoimmune Disease: A Collaborative And Interdisciplinary Program Of Research
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
The multi-organ autoimmune diseases ‘scleroderma’ and ‘lupus’ have a profound negative impact on quality of life and life expectancy. The overall goal of my research is to improve patient outcomes in these two diseases. My collaborative and interdisciplinary research program entails quantifying disease burden, identifying patient subsets, optimising screening for complications, developing outcome measures for use in practice and research, and trialing new therapies.
Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specificall ....Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specifically treat fibrosisRead moreRead less
The adult heart has an extremely limited capacity for regeneration. In contrast, I recently discovered that the newborn heart can completely regenerate following a heart attack. How and why the heart loses this regenerative capacity after birth is not known. This Fellowship aims to unravel the genetic circuits that govern cardiac regenerative capacity. The proposed research program will develop novel therapies for heart regeneration through molecular targeting of regulatory RNA molecules.
This research proposal will identify changes in liver-secreted proteins during the development of fatty liver, and in the transition from fatty liver to the more advanced form of liver disease, non-alcoholic steatohepatitis (NASH). Understanding the differences in protein secretion between NASH patients and patients with normal/fatty liver will provide the opportunity to identify disease biomarkers that could be determined from a blood sample. This will provide a major shift in clinical care.
Understanding The Mechanisms Underlying Airway Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
Changes in the structure of the lung contribute to the development of disease, but are not responsive to our current therapies. I have found two key structural proteins that are altered in asthma. This research will characterise the regulation and role of these proteins in the disease process. In addition, it will determine if these proteins also contribute to the development of other serious fibrotic diseases, for which there are no current treatments.
Dynamic Imaging Provides A New Perspective On Biological Function And Disease
Funder
National Health and Medical Research Council
Funding Amount
$391,076.00
Summary
Our ability to reduce the burden of disease is critically limited by our incapacity to image dynamic processes at the heart of those diseases. This application brings completely new capabilities to overcome this shortcoming and hence form new perspectives on several important medical problems that each result in alterations to dynamic processes: asthma, neonatal ventilation and cystic fibrosis within respiratory medicine and atherosclerosis and diabetes within cardiovascular medicine.
Airway scarring, or airway fibrosis, is a pathological process by which the airway tissue is progressively replaced with scar tissue. This change makes it difficult for people to breathe. I have developed novel in-vitro models which enables us to understand why fibrosis is occurring, and in my research fellowship I aim to uncover new ways of treating fibrosis in lung diseases such as asthma and chronic obstructive pulmonary disease (COPD).